Risk factors
Coherus Oncology (CHRS) risk factors
Item 1A of every Coherus Oncology, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors65 risks11 new22 dropped26 reworded
Coherus faces heightened competition and commercialization dependencies after divesting UDENYCA to focus on immuno-oncology pipelines like LOQTORZI.
Filed Mar 09, 2026 - FY2024 10-K risk factors76 risks
Company relies heavily on the pending sale of UDENYCA to Intas to pay off $230 million in convertible notes and $47.7 million in royalties.
Filed Mar 17, 2025